Aurora Biosciences Announces Webcast Conference Call Of First Quarter 2001 Financial Results

Apr 25, 2001, 01:00 ET from Aurora Biosciences Corporation

    SAN DIEGO, April 25 /PRNewswire/ -- Aurora Biosciences(R) Corporation
 (Nasdaq: ABSC) today announced that it will conduct a live audio webcast
 presentation of its first quarter 2001 earnings conference call at 2:00 PM
 Pacific Time on Thursday, May 3, 2001.  Stuart J.M. Collinson, Ph.D., Aurora's
 chairman, chief executive officer and president, will host the call.
 Management will review the first quarter operating results and provide its
 outlook for 2001.  Aurora will announce its financial results for first
 quarter 2001 in a press release to be issued after market close on Thursday,
 May 3, 2001.
     The press release and the live webcast presentation can be accessed at
 Aurora's website at http://www.aurorabio.com.  Investors, security analysts
 and representatives of the media who would like to participate by phone should
 dial (706) 643-1899 (domestic/international).  The webcast will be archived at
 Aurora's website until May 9, 2001.  A replay of the conference call will also
 be available from 6:00 PM Pacific Time on May 3, 2001 until 12:00 AM Pacific
 Time on May 9, 2001.  The dial in number is (800) 642-1687 (domestic) or (706)
 645-9291 (international) and the access code is 877695.
 
     Aurora Biosciences(R) is a drug discovery company that uses proprietary
 advances in biology, chemistry and automation to accelerate the discovery of
 new medicines.  Aurora's core technologies include a broad portfolio of
 proprietary fluorescence assay technologies and screening platforms designed
 to provide an integrated solution for drug discovery.  Aurora's fluorescence
 assay technologies include GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM) and Vivid(TM) technologies, as well as a broad collection
 of fluorescent proteins.  Aurora's screening platforms include an ultra-high
 throughput screening system, the UHTSS(R) Platform, Aurora's automated master
 compound store, the AMCS, and an ion channel technology screening platform,
 which includes Aurora's proprietary voltage sensor probes and a voltage ion
 probe reader, the VIPR(TM) subsystem.  Aurora also provides assay development
 and screening services as part of its drug discovery collaborations.  Aurora's
 Big Biology(TM) initiative is an internal drug discovery program focused on
 the identification of promising preclinical candidates within all major
 classes of gene targets.  Aurora's technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb, Ceres, Cystic Fibrosis Foundation, Eli Lilly, Families
 of SMA, GlaxoSmithKline, Genentech, Johnson & Johnson, Merck, NV Organon
 Laboratories, Pfizer, Pharmacia and Roche.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Such statements are only predictions and Aurora's
 actual events or results may differ materially from those projected in such
 forward-looking statements.  Factors that could cause or contribute to
 differences include Aurora's ability to develop and commercialize new
 technologies, as well as commercial acceptance of such technologies, Aurora's
 ability to rapidly identify promising drug candidates through its Big Biology
 initiative, Aurora's dependence on patents and proprietary rights, Aurora's
 ability to generate additional sales of products and services, Aurora's
 dependence on pharmaceutical and biotechnology collaborations and the
 development or availability of competing technologies, products or services.
 These factors and others are more fully described in Aurora's Annual Report on
 Form 10-K for the fiscal year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  For additional corporate information,
 visit the Aurora website at http://www.aurorabio.com.
 
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
 
     For further information please contact Doug Farrell, Senior Director,
 Investor Relations & Corporate Communications of Aurora Biosciences
 Corporation, 858-404-6767, or fax, 858-404-6714, ir@aurorabio.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X79414581
 
 

SOURCE Aurora Biosciences Corporation
    SAN DIEGO, April 25 /PRNewswire/ -- Aurora Biosciences(R) Corporation
 (Nasdaq: ABSC) today announced that it will conduct a live audio webcast
 presentation of its first quarter 2001 earnings conference call at 2:00 PM
 Pacific Time on Thursday, May 3, 2001.  Stuart J.M. Collinson, Ph.D., Aurora's
 chairman, chief executive officer and president, will host the call.
 Management will review the first quarter operating results and provide its
 outlook for 2001.  Aurora will announce its financial results for first
 quarter 2001 in a press release to be issued after market close on Thursday,
 May 3, 2001.
     The press release and the live webcast presentation can be accessed at
 Aurora's website at http://www.aurorabio.com.  Investors, security analysts
 and representatives of the media who would like to participate by phone should
 dial (706) 643-1899 (domestic/international).  The webcast will be archived at
 Aurora's website until May 9, 2001.  A replay of the conference call will also
 be available from 6:00 PM Pacific Time on May 3, 2001 until 12:00 AM Pacific
 Time on May 9, 2001.  The dial in number is (800) 642-1687 (domestic) or (706)
 645-9291 (international) and the access code is 877695.
 
     Aurora Biosciences(R) is a drug discovery company that uses proprietary
 advances in biology, chemistry and automation to accelerate the discovery of
 new medicines.  Aurora's core technologies include a broad portfolio of
 proprietary fluorescence assay technologies and screening platforms designed
 to provide an integrated solution for drug discovery.  Aurora's fluorescence
 assay technologies include GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM) and Vivid(TM) technologies, as well as a broad collection
 of fluorescent proteins.  Aurora's screening platforms include an ultra-high
 throughput screening system, the UHTSS(R) Platform, Aurora's automated master
 compound store, the AMCS, and an ion channel technology screening platform,
 which includes Aurora's proprietary voltage sensor probes and a voltage ion
 probe reader, the VIPR(TM) subsystem.  Aurora also provides assay development
 and screening services as part of its drug discovery collaborations.  Aurora's
 Big Biology(TM) initiative is an internal drug discovery program focused on
 the identification of promising preclinical candidates within all major
 classes of gene targets.  Aurora's technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb, Ceres, Cystic Fibrosis Foundation, Eli Lilly, Families
 of SMA, GlaxoSmithKline, Genentech, Johnson & Johnson, Merck, NV Organon
 Laboratories, Pfizer, Pharmacia and Roche.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Such statements are only predictions and Aurora's
 actual events or results may differ materially from those projected in such
 forward-looking statements.  Factors that could cause or contribute to
 differences include Aurora's ability to develop and commercialize new
 technologies, as well as commercial acceptance of such technologies, Aurora's
 ability to rapidly identify promising drug candidates through its Big Biology
 initiative, Aurora's dependence on patents and proprietary rights, Aurora's
 ability to generate additional sales of products and services, Aurora's
 dependence on pharmaceutical and biotechnology collaborations and the
 development or availability of competing technologies, products or services.
 These factors and others are more fully described in Aurora's Annual Report on
 Form 10-K for the fiscal year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  For additional corporate information,
 visit the Aurora website at http://www.aurorabio.com.
 
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
 
     For further information please contact Doug Farrell, Senior Director,
 Investor Relations & Corporate Communications of Aurora Biosciences
 Corporation, 858-404-6767, or fax, 858-404-6714, ir@aurorabio.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X79414581
 
 SOURCE  Aurora Biosciences Corporation